Michael Rabenstein

Overview
Related items

About Michael Rabenstein:

No description specified

SEEK ID: https://cgnbonn.fdm.digital-medicine.org/people/4

Locations: Germany , Not specified

ORCID: https://orcid.org/0000-0001-7712-224X

Joined: 8th Oct 2024

Expertise: Not specified

Tools: Not specified

Their tags

This person has not yet tagged anything.

Related items

Advanced Trial Projects list for this Person with search and filtering

MDS User Guide I

An example project, showing how the metadata scheme should be filled.

Public web page: Not specified

Start date: 3rd Dec 2024

End date: 2nd Dec 2124

Organisms: Not specified

Test MR

No description specified

Public web page: Not specified

Organisms: Not specified

Cancer rehabilitation support by cancer counseling centers (CARES)

The present study is a feasibility study. The aim is to develop intensified and needs-oriented support for the return to work of oncological patients with uncertain vocational reintegration prognosis by counselors in cancer counseling centers and to investigate the acceptance, feasibility and implementation conditions. Within the feasibility study, survey data of advice seekers with and without intensified counseling will be collected. The recruitment of the advice seekers is a sequential survey ...

Public web page: https://www.ukbonn.de/chsr/projekte/

Start date: 25th Apr 2022

Organisms: Not specified

Advanced Institutions list for this Person with search and filtering

IDM

Country: Germany

City: Not specified

Web page: Not specified

User Guide

Country: Not specified

City: Not specified

Web page: Not specified

Advanced Publications list for this Person with search and filtering

Berufsbezogene Beratung im Rahmen der Cancer-Rehabilitation-Support-by-Cancer-Counseling-Centers(CARES)-Studie

Cancer rehabilitation support by cancer counseling centers (CARES)

Abstract (Expand)

**Hintergrund** Bei Krebsbetroffenen im erwerbsfähigen Alter stellen sich von Diagnose und Behandlungsbeginn an zumeist auch arbeitsbezogene Fragestellungen. In der CARES-Studie (Cancer Rehabilitation …

Authors: Clara Breidenbach, Paula Heidkamp, Kati Hiltrop, Lina Heier, Johanna Weiß, Marie Rösler, Sabine Schneider, Sophie Schellack, Johannes Soff, Christoph Kowalski, Nicole Ernstmann

Date Published: 2nd Aug 2024

Publication Type: Journal

DOI: 10.1007/s00761-024-01565-4

Citation: Onkologie

Created: 28th Oct 2024 at 12:12, Last updated: 28th Oct 2024 at 12:22

Cancer rehabilitation support by cancer counselling centres (CARES): study protocol of a quasi-experimental feasibility study.

Cancer rehabilitation support by cancer counseling centers (CARES)

Abstract (Expand)

INTRODUCTION: While maintaining or restoring work ability after a cancer diagnosis is an essential aim of the rehabilitation process for working-age patients, problems can arise during the return to … work (RTW) or when retaining work. Counselling could provide support for patients with or after cancer with employment-related questions (eg, questions related to RTW and work retention). Outpatient psychosocial cancer counselling centres in Germany offer counselling on work-related questions; however, resources for this are limited. This protocol presents a feasibility study of an intensified needs-based counselling intervention that supports those seeking employment-related advice. METHODS AND ANALYSIS: The CARES (cancer rehabilitation support by cancer counselling centres) project is a feasibility study for a newly developed counselling intervention. The intervention is being developed as part of the project and piloted in about 20 outpatient cancer counselling centres. The CARES study has a quasi-experimental pre-post design with a control cohort. First, patients who undergo regular counselling are recruited. Second, after the counsellors have been trained for the newly developed intervention, participants for the intervention group are recruited from the cancer counselling centres. Quantitative and formative evaluations will be performed in accordance with the existing guidelines. The quantitative evaluation comprises three patient surveys (at the beginning of the counselling process, 3 months into the counselling process and, for the intervention group, at the end of the counselling process) and routine data of the counselling process. The formative evaluation includes interviews with patients, counsellors and other stakeholders, as well as participatory observations of counselling sessions. ETHICS AND DISSEMINATION: Approval has been obtained from the ethics committee of the Medical Faculty of the University Bonn (061/22; 09.04.2022). A data protection concept ensures adherence to data protection regulations for the handled data. The dissemination strategies include discussing the results with the cancer counselling centres. TRIAL REGISTRATION NUMBER: German Clinical Trials Register (DRKS00028121); Pre-results.

Authors: K. Hiltrop, P. Heidkamp, C. Breidenbach, C. Kowalski, G. Bruns, N. Ernstmann

Date Published: 11th Aug 2023

Publication Type: Journal

PubMed ID: 37567747

Citation: BMJ Open. 2023 Aug 11;13(8):e067868. doi: 10.1136/bmjopen-2022-067868.

Created: 21st Oct 2024 at 10:43

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.

Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance treatment

Abstract (Expand)

The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in …

Authors: H. Goldschmidt, E. K. Mai, J. Durig, C. Scheid, K. C. Weisel, C. Kunz, U. Bertsch, T. Hielscher, M. Merz, M. Munder, H. W. Lindemann, B. Hugle-Dorr, D. Tichy, N. Giesen, D. Hose, A. Seckinger, S. Huhn, S. Luntz, A. Jauch, A. Elmaagacli, B. Rabold, S. Fuhrmann, P. Brossart, M. Goerner, H. Bernhard, M. Hoffmann, J. Hillengass, M. S. Raab, I. W. Blau, M. Hanel, H. J. Salwender

Date Published: 9th Feb 2020

Publication Type: Journal

PubMed ID: 32034285

Citation: Leukemia. 2020 Jul;34(7):1853-1865. doi: 10.1038/s41375-020-0724-1. Epub 2020 Feb 7.

Created: 5th Nov 2024 at 16:17

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Abstract

Not specified

Authors: M. Merz, H. Salwender, M. Haenel, E. K. Mai, U. Bertsch, C. Kunz, T. Hielscher, I. W. Blau, C. Scheid, D. Hose, A. Seckinger, A. Jauch, J. Hillengass, M. S. Raab, B. Schurich, M. Munder, P. Brossart, C. Gerecke, H. W. Lindemann, M. Zeis, K. Weisel, J. Duerig, H. Goldschmidt

Date Published: 20th Aug 2016

Publication Type: Journal

PubMed ID: 27540135

Citation: Haematologica. 2016 Dec;101(12):e485-e487. doi: 10.3324/haematol.2016.151266. Epub 2016 Aug 18.

Created: 5th Nov 2024 at 16:18

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Abstract (Expand)

We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial …

Authors: E. K. Mai, U. Bertsch, J. Durig, C. Kunz, M. Haenel, I. W. Blau, M. Munder, A. Jauch, B. Schurich, T. Hielscher, M. Merz, B. Huegle-Doerr, A. Seckinger, D. Hose, J. Hillengass, M. S. Raab, K. Neben, H. W. Lindemann, M. Zeis, C. Gerecke, I. G. Schmidt-Wolf, K. Weisel, C. Scheid, H. Salwender, H. Goldschmidt

Date Published: 20th Mar 2015

Publication Type: Journal

PubMed ID: 25787915

Citation: Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

Created: 5th Nov 2024 at 16:18